Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study.
Szu-Min HsiehShan-Chwen ChangHao-Yuan ChengShin-Ru ShihChia En LienPublished in: Infectious diseases and therapy (2022)
ClinicalTrials.gov identifier NCT04487210.